See all news

Investigational drugs didn’t slow memory loss, cognitive decline in rare, inherited Alzheimer’s, initial analysis indicates

Representatives from Washington University School of Medicine, Eli Lilly and Co. and Roche convened Feb. 3 on the Washington University Medical Campus, to discuss data from the DIAN-TU trial. The international trial evaluated whether investigational drugs could slow memory loss and cognitive decline in people with a rare, inherited form of early-onset Alzheimer’s disease. Led by the School of Medicine, the trial evaluated investigational medicines made by Lilly and by Roche and its U.S. affiliate, Genentech. The DIAN-TU is grateful for the wonderful collaboration with our partners from Lilly and Roche, pictured here (counterclockwise): Randall Bateman (DIAN-TU); John Sims and Scott Andersen (Lilly); Janice Hitchcock (DIAN-TU); Isabella Velona and Cheryl Brown (Lilly); Susan Mills (DIAN-TU); Roy Yaari and Karen Holdridge (Lilly); From Roche: Kimberly Kyle, Geoff Kerchner, Alison Searle, Paul Delmar, Monika Baudler-Klein, and Rachelle Doody

View News Article

Categories: DIAN-TU Announcement